The American Journal of Managed Care

Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows ...
Becker's Hospital Review

FDA clears 1st smart multiple daily injection system for diabetes

The FDA has granted 510(k) clearance to Medtronic for its MiniMed “Go Smart” multiple daily injection system — the first ...
Monthly Prescribing Reference

Biweekly Dosing Approved for Tecvayli in Relapsed/Refractory Multiple Myeloma

The new biweekly dosing regimen for Tecvayli is intended for patients with RRMM who have achieved and maintained a complete response or better for a minimum of 6 months. The Food and Drug ...
Seeking Alpha

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of ...
Seeking Alpha

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

"TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today's approval of biweekly dosing for eligible patients will further enable clinicians to meet the individual needs ...